According to the Zhitong Finance App, Hanson Pharmaceuticals (03692.HK) announced that the B7-H3 targeted antibody-drug conjugate (ADC) HS20093, which was independently developed by the group, reached the main end of overall survival (OS) in critical phase III clinical trials (ARTEMIS-008) for patients with small cell lung cancer (SCLC) that progressed or recurred after platinum-containing treatment. When analyzed in the pre-set period, compared with topotecan, HS-20093 showed statistically significant and clinically significant improvements in OS, and consistent benefits were also observed at secondary clinical endpoints, including progression-free survival (PFS). The safety characteristics are consistent with the results of previous studies, and no new safety signals were found.

According to the Zhitong Finance App, Hanson Pharmaceuticals (03692.HK) announced that the B7-H3 targeted antibody-drug conjugate (ADC) HS20093, which was independently developed by the group, reached the main end of overall survival (OS) in critical phase III clinical trials (ARTEMIS-008) for patients with small cell lung cancer (SCLC) that progressed or recurred after platinum-containing treatment. When analyzed in the pre-set period, compared with topotecan, HS-20093 showed statistically significant and clinically significant improvements in OS, and consistent benefits were also observed at secondary clinical endpoints, including progression-free survival (PFS). The safety characteristics are consistent with the results of previous studies, and no new safety signals were found.